moxifloxacin has been researched along with Diabetes Mellitus, Type 2 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Xu, S; Zhou, M; Zhu, F | 1 |
| Ahmed Khan, T; Azher, I; Sheikh, AK; Sheikh, M | 1 |
| von Hallern, B | 1 |
| Boldrin, M; Zhai, S; Zhi, J | 1 |
| Chatterjee, DJ; Khutoryansky, N; Litwin, JS; Sprenger, CR; Zdravkovic, M | 1 |
| Czaika, V; Drewelow, B; Gussmann, A; Klar, E; Koch, H; Kujath, P; Lobmann, R; Luebbert, C; Majcher-Peszynska, J; Mundkowski, RG; Ruf, BR; Sass, M; Schareck, W; Schipper, S | 1 |
| Hand, DL; Hand, WL; Vasquez, Y | 1 |
3 trial(s) available for moxifloxacin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Dose-Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short-Term Multiple Doses in Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Benzeneacetamides; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin | 2017 |
Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.
Topics: Adolescent; Adult; Aza Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electrocardiography; Female; Fluoroquinolones; Glucagon-Like Peptide 1; Heart Conduction System; Humans; Injections, Subcutaneous; Liraglutide; Male; Middle Aged; Models, Statistical; Moxifloxacin; Quinolines; Time Factors | 2009 |
Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines | 2011 |
4 other study(ies) available for moxifloxacin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
Topics: Anti-HIV Agents; Betacoronavirus; China; Clinical Laboratory Techniques; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Testing; Diabetes Mellitus, Type 2; Drug Combinations; gamma-Globulins; HIV; HIV Infections; Humans; Lopinavir; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Burn aggravated infected wart in a patient with type 2 diabetes: a medical challenge.
Topics: Aged; Anti-Bacterial Agents; Burns; Cefepime; Cephalosporins; Diabetes Mellitus, Type 2; Fluoroquinolones; Foot; Foot Diseases; Humans; Male; Moxifloxacin; Pakistan; Saudi Arabia; Staphylococcal Infections; Staphylococcus aureus; Warts | 2018 |
Case 7: highly infected post-surgical wound.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Cefuroxime; Diabetes Mellitus, Type 2; Exudates and Transudates; Fluoroquinolones; Humans; Imines; Male; Metronidazole; Moxifloxacin; Pyridines; Surgical Wound Infection; Therapeutic Irrigation | 2016 |
Increased polymorphonuclear leukocyte respiratory burst function in type 2 diabetes.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Fluoroquinolones; Humans; Male; Mexican Americans; Moxifloxacin; Neutrophils; Ofloxacin; Protein Kinase C; Quinolines; Respiratory Burst; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 2007 |